Why Ocugen Stock Rose, Then Slipped Today
Somewhat of an outlier coronavirus stock, Ocugen (NASDAQ: OCGN) see-sawed in price on Monday. That followed a new analyst recommendation, which although very bullish, likely gave investors pause to think about the company's prospects.
Noble Capital analyst Robert LeBoyer initiated coverage of the stock with an unhesitant outperform (i.e., buy) recommendation. He also placed a $15 per share target price on the stock, which is more than double the level the shares closed at on Friday.
Image source: Getty Images.
Source Fool.com
